Initial chemotherapy in gliomatosis cerebri

Sanson, Marc; Cartalat‐Carel, Stéphanie; Taillibert, Sophie; Napolitano, Massimo; Djafari, L.; Cougnard, Jean; Gervais, H.; Laigle, F.; Carpentier, Alexandre; Mokhtari, Karima; Taillandier, Luc; Chinot, Olivier; Duffau, Hugues; Honnorat, Jérôme; Hoang-Xuân, Khê; Delattre, Jean‐Yves

doi:10.1212/01.wnl.0000129985.39973.e4

Cited by 107 publications

(109 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, RT is recommended even for children who potentially have higher susceptibility for radiation. [6] In the present case, the patient deceased in 5 months after initial diagnosis, which is just as short as reported in the study in the group without WBRT. [2] This case supports the necessity of RT in order to accomplish better OS or PFS.…”

Section: Discussionsupporting

confidence: 52%

“…[2] Chemotherapy for GC had not been considered as effective treatments even combined with radiation therapy (RT), [5] but recent growing publications support its efficacy to certain extent. [6] Chemotherapy with temozolomide is widely used recently, because of its safety. It has, however, insufficient effect to GC, and combination with RT is considered essential.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric gliomatosis cerebri presenting with intratumoral hemorrhage leading to poor outcome

Adachi¹,

Kitagawa²,

Kawasaki³

et al. 2016

JCMT

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Pediatric gliomatosis cerebri presenting with intratumoral hemorrhage leading to poor outcome

Adachi¹,

Kitagawa²,

Kawasaki³

et al. 2016

JCMT

View full text Add to dashboard Cite

“…3 Extent of resection is a prognostic factor in these tumors, too. 7,15 Although RT (54)(55)(56)(57)(58)(59)(60) Gy, 1.8-2 Gy-fractions) has been considered standard of care for anaplastic oligodendroglial tumors, their chemosensitivity to nitrosoureas and TMZ has long been recognized, and ongoing controversies do not focus on whether to give RT or alkylating chemotherapy at all, but rather when and in what sequence. Long-term results of the two early large independent randomized clinical trials -EORTC 26951 and Radiation Therapy Oncology Group (RTOG) 9402 -that explored the value of PCV polychemotherapy, either prior to or immediately after RT, indicate that the inclusion of chemotherapy in the first-line treatment confers a survival advantage which becomes evident only after follow-up of more than six years and only in the subgroup of patients with 1p/19q-co-deleted tumours.…”

Section: Anaplastic Oligodendroglioma and Oligoastrocytoma -Who Gradementioning

confidence: 99%

“…55,56 The NOA-05 trial explored the efficacy of primary PC chemotherapy, omitting vincristine because of poor blood brain barrier penetration, and observed treatment failure at 8 months in less than half of the patients, and a median overall survival of 30 months. 54 …”

Section: Gliomatosis Cerebri Imaging Resembles Diffuse (Who Grade Ii)mentioning

confidence: 99%

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Weller

Bent

Hopkins

et al. 2014

The Lancet Oncology

669

532

View full text Add to dashboard Cite

This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures. AF and DF report no conflicts of interest. FundingThe preparation of this guideline was not funded. The members of the task force did not receive compensation for their participation. 5 SummaryThis guideline provides recommendations for the diagnostic and therapeutic procedures for patients with malignant gliomas. It differentiates evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein shall provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline will contribute to a critical appreciation of concurrent medications with a focus on the controlled use of anticonvulsants and steroids. It shall serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarized here will require interdisciplinary structures of care for brain tumor patients and structured processes of diagnostic and therapeutic procedures. Key wordsAnaplastic, glioma, glioblastoma, surgery, radiotherapy, temozolomide, bevacizumab Search strategy and selection criteriaThis guideline was prepared by a task force assembled by the Executive Committee of the European Association for Neuro-Oncology (EANO) in 2013. The task force was designed to represent the different disciplines involved in the diagnosis and care of malignant glioma patients as well as to reflect the multinational composition of EANO.References for this review were identified through searches of PubMed with the search terms "glioma", "anaplastic", "glioblastoma", "trial", "clinical", "radiotherapy" 6 and "chemotherapy" from January 2005 to January 2013. Articles were also identified through searches of the authors` own files. Onl...

show abstract

“…It frequently extends bilaterally and has been assigned a WHO grade of III [32]. In symptomatic [47]. A clinical benefit was suggested for both regimens, with progression-free survival and overall survival times of 16 and 29 months, respectively.…”

Section: Gliomatosis Cerebrimentioning

confidence: 99%

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Stupp

Hegi

Bent³

et al. 2006

The Oncologist

370

241

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. List the different major subtypes of glioma and identify the appropriate treatment strategies for patients with high-grade and low-grade gliomas.2. Discuss the available evidence for the treatment of newly diagnosed glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma.3. Identify approved agents and other active or investigational agents used to treat patients with newly diagnosed and recurrent glioma. shown that early neoadjuvant or adjuvant administration of procarbazine, lomustine, and vincristine chemotherapy prolongs disease-free survival; however, it has no impact on overall survival. Temozolomide, a novel alkylating agent, has shown modest activity against recurrent glioma. In combination with radiotherapy in newly diagnosed patients with glioblastoma, temozolomide significantly prolongs survival. Molecular studies have demonstrated that the benefit is mainly observed Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Initial chemotherapy in gliomatosis cerebri

Abstract: Initial chemotherapy is useful for some patients with gliomatosis cerebri. Temozolomide is well tolerated and appears to be a valuable alternative to procarbazine-CCNU-vincristine, especially for those with slow-growing, low-grade GC.

Cited by 107 publications

References 29 publications

Pediatric gliomatosis cerebri presenting with intratumoral hemorrhage leading to poor outcome

Pediatric gliomatosis cerebri presenting with intratumoral hemorrhage leading to poor outcome

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Contact Info

Product

Resources

About